Centre for Youth Mental Health - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Investigating the cause and maintenance of Anorexia Nervosa - The I-CAN study: Protocol and open call for study sites and collaboration
    Phillipou, A ; Croce, S ; Abel, LA ; Castle, DJ ; Dean, B ; Eikelis, N ; Elwyn, R ; Gurvich, C ; Jenkins, Z ; Meyer, D ; Miles, S ; Neill, E ; Ralph-Nearman, C ; Rocks, T ; Rossell, SL ; Ruusunen, A ; Simpson, TN ; Urbini, G ; West, M ; Malcolm, A (ELSEVIER IRELAND LTD, 2023-10)
  • Item
    Thumbnail Image
    Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology
    Dean, B ; Thomas, EHX ; Bozaoglu, K ; Tan, EJ ; Rheenen, TEV ; Neill, E ; Sumner, PJ ; Carruthers, SP ; Scarr, E ; Rossell, SL ; Gurvich, C (ELSEVIER IRELAND LTD, 2022-11)
    It is suggested studying phenotypes within the syndrome of schizophrenia will accelerate understanding the complex molecular pathology of the disorder. Supporting this hypothesis, we have identified a sub-group within schizophrenia with impaired working memory (WM) and have used Affymetrix™ Human Exon 1.0 ST Arrays to compare their blood RNA levels (n=16) to a group of with intact WM (n=18). Levels of 72 RNAs were higher in blood from patients with impaired WM, 11 of which have proven links to the maintenance of different aspects of working memory (cognition). Overall, changed gene expression in those with impaired WM could be linked to cognition through glutamatergic activity, olfaction, immunity, inflammation as well as energy and metabolism. Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning. In addition, our data raises the possibility that a larger study could show that the specific changes in gene expression we have identified could prove to be the biomarkers needed to develop a blood test to identify those with impaired WM; a significant step toward allowing the use of personalised medicine directed toward improving their impaired working memory.